clinical trial · NCT05913232
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
D. Western Therapeutics Institute, Inc.·phase2·completed·n = 201
Glaucoma Open-Angle PrimaryOcular HypertensionH-1337 0.6%H-1337 1.0%H-1337 PlaceboTimolol 0.5%
brief summary
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
started
Aug 28, 2023
primary completion
Aug 29, 2024
completion
Aug 29, 2024
last updated
Aug 27, 2025
official title
A Phase 2b Randomized, Double-masked, Active-controlled, Dose-response Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol